Craft
Loxo Oncology

Loxo Oncology

Loxo Oncology Summary

Company summary

Overview
Loxo Oncology is dedicated to developing highly selective medicines for patients with genetically defined cancers. The Company bases its approach on two scientific trends: the increasing use of genetic testing in cancer clinical medicine and improving chemistry approaches to building highly selective inhibitors against single targets in the cancer cell. Loxo Oncology is developing a pipeline of highly selective drugs that inhibit oncogenic drivers in cancer.
Type
Subsidiary
Status
Active
Founded
2013
HQ
Stamford, CT, US | view all locations
Website
http://www.loxooncology.com/
Cybersecurity rating
Sectors

Key people

  • Jacob S. van Naarden, Chief Executive Officer

    • Nisha Nanda

      Nisha Nanda, Chief Development Officer

    • David Hyman, Chief Medical Officer

      • Steve Andrews, Senior Vice President, Small Molecule Discovery

        LocationsView all

        5 locations detected

        • Stamford, CT HQ

          United States

          281 Tresser Blvd, 14th Floor

        • Boulder, CO

          United States

          3122 Sterling Cir #200

        • New York, NY

          United States

          450 E 29th St

        • South San Francisco, CA

          United States

          701 Gateway Blvd #420

        • Alcobendas, Comunidad de Madrid

          Spain

          Av. de la Industria, 30

        Loxo Oncology Financials

        Summary financials

        Revenue (Q3, 2018)
        $42.5M
        Net income (Q3, 2018)
        ($27.1M)
        Cash (Q3, 2018)
        $136.1M
        EBIT (Q3, 2018)
        ($30.3M)

        Footer menu